Lilly's New Weight-Loss Drug Is So Powerful It's Competing With Surgery
Eli Lilly's retatrutide, a triple gut-hormone agonist, just posted Phase 3 weight loss numbers that rival bariatric surgery: nearly 29% body weight gone in 80 weeks. The obesity drug race just got a new frontrunner, and the competition is scrambling.
Imagine a world where a weekly injection could replace gastric bypass. Eli Lilly just nudged us closer to that reality.
The pharma giant dropped Phase 3 data for retatrutide, a once-weekly shot that targets not one, not two, but three gut hormone receptors. The result: patients in TRIUMPH-1 lost 28.3% of their body weight over 80 weeks, while those in TRIUMPH-4 lost 28.7% over 68 weeks. Those are the kinds of numbers that used to require a surgeon, a hospital stay, and a permanently altered digestive system.
The Triple Threat Nobody Saw Coming (Except Lilly)
Most obesity drugs on the market right now hit one or two hormonal pathways. Wegovy (semaglutide) targets GLP-1 alone. Zepbound (tirzepatide), also made by Lilly, hits both GLP-1 and GIP. Think of these receptors as volume knobs for hunger, metabolism, and blood sugar. The more knobs you turn, the more dramatic the effect.
Retatrutide turns all three: GLP-1, GIP, and glucagon. That glucagon piece is the wild card. Glucagon tells your liver to burn stored energy, essentially lighting a metabolic fire on top of the appetite suppression the other two receptors provide. It's like adding a turbocharger to an engine that was already fast.
The drug is the centerpiece of Lilly's TRIUMPH clinical program, which spans multiple Phase 3 trials across different patient populations.
The Numbers That Made Wall Street Take Notice
Lilly's TRIUMPH-1 trial enrolled adults with obesity (no diabetes) and ran for 80 weeks. Patients on the highest dose (12 mg) lost an average of 28.3% of their body weight. On the 9 mg dose, they lost about 26%.
Those are the "best case" numbers, calculated assuming patients stayed on the drug the whole time.
Perhaps the most jaw-dropping detail: a subset of patients who continued the 12 mg dose out to 104 weeks hit nearly 30% weight loss. The curve still hadn't flattened. These patients were still losing weight after two full years.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
It's Not Just About the Scale
A separate trial, TRIUMPH-4, tested retatrutide in people who had both obesity and painful knee osteoarthritis. This is a population that desperately needs effective weight loss; every extra pound puts roughly four pounds of pressure on a damaged knee.
The results were striking on two fronts. Patients on the 12 mg dose lost 28.7% of their body weight over 68 weeks (roughly 71 pounds from a baseline around 248). But their knee pain scores also plummeted by about 76%, measured on a standard osteoarthritis pain scale called WOMAC.
In patients with type 2 diabetes, a 40-week trial called TRANSCEND showed the drug delivered up to 16.8% weight loss alongside a 2.0-point drop in A1C (the key blood sugar marker). And the weight loss curve still hadn't plateaued at study's end. Longer treatment would likely mean bigger numbers.
How It Stacks Up Against the Competition
This is where things get interesting for investors and patients alike.
Lilly's own Zepbound, currently the market leader, produces around 21% weight loss at 72 weeks in its landmark trial. Novo Nordisk's Wegovy typically delivers about 13 to 15%. Retatrutide at 28% isn't just beating these drugs; it's playing a different sport.
Novo isn't sitting still, though. Its next-gen candidate, CagriSema (semaglutide plus a long-acting amylin analogue called cagrilintide), showed about 22.7% weight loss at 68 weeks in Phase 3. That fell short of the company's internal 25% target and disappointed investors. Novo is also fast-tracking amycretin, a single-molecule GLP-1/amylin agonist that hit roughly 24% weight loss in just 36 weeks of early testing. If that trajectory holds over a full-length trial, it could be retatrutide's closest competitor.
But for now, retatrutide sits alone at the top of the efficacy leaderboard.
Wall Street's Verdict: Strong, With a Caveat
Analysts broadly praised the data. RBC Capital Markets called it a "clean win" with a solid safety profile. Multiple firms described the results as "best-in-class."
But not everyone was popping champagne. BMO Capital Markets had modeled 27 to 28.5% total weight loss as their expected range, and the actual number fell slightly below the upper end. Citi was more measured, calling retatrutide a "more niche market opportunity" compared to Zepbound and Lilly's upcoming oral option, orforglipron.
That "niche" framing deserves some context. It doesn't mean small. It means retatrutide probably won't be the first drug doctors prescribe for someone looking to lose 30 pounds. Instead, it's likely to be reserved for patients with severe obesity, complex health problems, or those who didn't respond well enough to dual-agonist drugs like Zepbound.
Think of it as Lilly building a weight-loss ladder: oral pills at the base for broad access, Zepbound in the middle for strong results, and retatrutide at the top for maximum firepower.
The Tolerability Question
More power usually means more side effects, and retatrutide is no exception. GI issues (nausea, diarrhea, constipation) are common across the entire class of gut-hormone drugs. Earlier retatrutide studies had raised concerns about unusual nerve-related sensations called dysesthesia.
The good news from TRIUMPH-1: tolerability improved compared to earlier data. About 18% of patients on the highest dose discontinued due to side effects. And the 4 mg dose was a standout, with a discontinuation rate of just 4%, actually lower than placebo.
Analysts flagged this dose flexibility as a potential commercial weapon. Lilly can offer doctors a spectrum: gentle 4 mg for patients who are side-effect-sensitive, aggressive 12 mg for those who want maximum results.
What Happens Next
Lilly is expected to file for FDA approval in 2026, with additional data from trials targeting sleep apnea and cardiovascular disease still rolling in. Each positive readout could expand the drug's eventual label and commercial reach.
The bigger picture? Lilly now has a three-tiered obesity arsenal (oral orforglipron, injectable Zepbound, injectable retatrutide) that no competitor can match in breadth or depth. Novo Nordisk has the brand recognition and first-mover advantage with Wegovy, but it's scrambling to close an efficacy gap that retatrutide just made wider.
For the estimated 100 million-plus Americans living with obesity, though, the competition itself is the real win. Every new drug that enters this race pushes the others to be better, cheaper, or both. And a world where a weekly shot can safely deliver surgery-level weight loss? That's not a future anymore. It's Phase 3 data.
Funding & Financings4 min read
Google's Secret Weapon Just Raised More Than Most Biotechs Are Worth
Isomorphic Labs, the Google DeepMind spinoff, just raised $2.1 billion in the largest AI drug discovery financing ever. With Nobel Prize-winning science, $3 billion in pharma deals, and zero approved drugs, the company is making the biggest bet the field has ever seen.
